Session » 4M096: Spondyloarthritis Including Psoriatic Arthritis – Clinical III: Miscellaneous (1818–1823)

Date: Monday, November 11, 2019

Time: 2:30PM-4:00PM

Meeting: 2019 ACR/ARP Annual Meeting

2:30PM-4:00PM: Abstract Number: 1822

6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network

2:30PM-4:00PM: Abstract Number: 1820

Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient

2:30PM-4:00PM: Abstract Number: 1818

Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study

2:30PM-4:00PM: Abstract Number: 1823

Magnetic Resonance Enterography as a Screening Tool to Detect Sacroiliitis in Crohn’s Disease: Association with Clinical and Endoscopic Markers of Crohn’s Disease Activity

2:30PM-4:00PM: Abstract Number: 1819

The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index

2:30PM-4:00PM: Abstract Number: 1821

Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].